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Abstract Increased glucose uptake mediated by glucose
transporters and reliance on glycolysis are common features
of malignant cells. Hypoxia-inducible factor-1α supports the
adaptation of hypoxic cells by inducing genes related to
glucose metabolism. The contribution of glucose transporter
(GLUT) and hypoxia-inducible factor-1α (HIF-1α) activity to
tumor behavior and their prognostic value in head and neck
cancers remains unclear. The aim of this study was to examine
the predictive value of GLUT1, GLUT3, and HIF-1α mes-
senger RNA (mRNA)/protein expression as markers of tumor
aggressiveness and prognosis in laryngeal cancer. The level of
hypoxia/metabolic marker genes was determined in 106 squa-
mous cell laryngeal cancer (SCC) and 73 noncancerous
matched mucosa (NCM) controls using quantitative real-
time PCR. The related protein levels were analyzed by
Western blot. Positive expression of SLC2A1, SLC2A3, and
HIF-1α genes was noted in 83.9, 82.1, and 71.7 % of SCC
specimens and in 34.4, 59.4, and 62.5 % of laryngeal cancer
samples. Higher levels of mRNA/protein for GLUT1 and
HIF-1α were noted in SCC compared to NCM (p<0.05).
SLC2A1 was found to have a positive relationship with grade,
tumor front grading (TFG) score, and depth and mode of
invasion (p<0.05). SLC2A3 was related to grade and invasion
type (p<0.05). There were also relationships of HIF-1α with
pTNM, TFG scale, invasion depth and mode, tumor recur-
rences, and overall survival (p<0.05). In addition, more ad-
vanced tumors were found to be more likely to demonstrate
positive expression of these proteins. In conclusion, the
hypoxia/metabolic markers studied could be used as molecu-
lar markers of tumor invasiveness in laryngeal cancer.
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Introduction
Over the past decade, research has been focused on the mech-
anisms through which various types of neoplasms might take
a more malignant phenotype and form more aggressive cell
clones which can determine tumor development and progres-
sion. It is well known that the rapid proliferation of malignant
cells causes the formation of hypoxic areas within the stroma
of solid human tumors [1]. Hypoxia is able to induce many
changes in the physiological processes and biochemistry of
malignant cells by upregulating the expression of a number of
target genes, inter alia those related to glucose metabolism
and glucose transport, angiogenesis, invasion, and metastasis,
in order to adapt to anaerobic conditions [1–5]. The results of
many studies have provided evidence of the carcinogenic
effects of the inhibition of the oxidative phosphorylation
process and conversion into enhanced aerobic glycolysis,
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known as theWarburg effect, which is associated with the
activity of key factors in glucose metabolism like glu-
cose transporters (GLUTs) and their most important
regulatory hypoxia-related protein, hypoxia-inducible
factor-1α (HIF-1α) [6].
Until now, 14 members of the GLUT family coded by
genes belonging to the solute carrier 2A family (SLC2A) have
been identified [7]. Numerous in vivo and in vitro studies
suggest that the biological activity of GLUT isoforms and
their participation in many regulatory mechanisms involving,
among others, the phosphatidylinositol-3-kinase (PI3K)/Akt
pathway, NF-κB activity, and wild-type p53 protein expres-
sion may contribute to cancer development [8–11]. GLUTs
also promote the epithelial-mesenchymal transition (EMT),
cell migration, invasion, and metastasis by the regulation of
matrix metalloproteinase (MMP) activity [12]. Other mecha-
nisms of carcinogenesis are HIF-1α activity in EMT via the
inhibition of E-cadherin and promotion ofMMP-2 and SNAI1
expression, the regulation of the PI3K/Akt pathway, as well as
VEGF activation [3, 4, 13, 14].
A literature review reveals the contribution of aberrant
various glucose uptake transporter isoforms and metabolism/
hypoxia regulators to the tumorigenesis and progression of
various head and neck cancers [8, 15–22]. Unfortunately, the
clinical importance of alternations in glucose metabolism and
GLUT expression in these malignances is largely unknown.
Most reviews focus on the association between cellular level
of GLUTs and both tumor aggressiveness and disease out-
come [8, 15–22]. Unfortunately, other studies have reported
not only contradictory results and inverse interconnections,
but also a lack of any association between the expression of
metabolism/hypoxia endogenous markers with either clinico-
pathological tumor features or patient prognosis [23–26].
Despite conflicting data, research reveals that the identifi-
cation of changes in cancer metabolism reprogramming based
on GLUT isoform expression, as well as the oncogenic mech-
anisms leading to increased aerobic glycolysis, may be con-
sidered as potential new therapeutic targets for treatment
strategies. They may also be used in synergy with conven-
tional treatments to alter and/or inhibit cancer invasiveness
and progression. Therefore, many authors propose the sup-
pression of SLC2A1 and SLC2A3 genes by the use of anti-
sense oligodeoxynucleotides which decrease glucose uptake,
inhibit the proliferation of malignant cells, and enhance of
radiosensitivity and chemosensitivity. This in turn allows the
optimal treatment modality of neoplastic lesions, between
them cancers of the head and neck region [12, 27, 28].
Less controversy surrounds the expression of HIF-1α, the
endogenous regulator of glucose metabolism mechanisms in
hypoxia conditions, with regard to clinicopathological param-
eters in various types of head and neck neoplasms. Previous
studies indicate that cancer cells appear to display overexpres-
sion of this metabolic hypoxia-related protein in most tumor
cases, and a high HIF-1α level is related to an enhanced grade
of tumor aggressiveness, higher incidences of metastasis, and
poor prognosis [26, 29–31]. However, a literature review
reveals the conflicting results related to HIF-1α expression
and its relationship with clinical features in various neoplastic
lesions [4, 32, 33].
Unfortunately, it is hard to find literature data which clearly
demonstrates the clinical importance of the relationship be-
tween HIF-1α level and GLUT isoform activity, as well as a
precise multifactorial histological estimation of their influence
on neoplastic aggressiveness in head and neck cancers. Hence,
more studies are needed to elucidate the biological functions
of both GLUTs and regulatory molecule HIF-1α in the carci-
nogenic process, and their possible clinical significance as
parameters of tumor invasiveness and prognostic factors in
this type of neoplasm.
The aim of this study was to determine the messenger RNA
(mRNA) expression of SLC2A1 and SLC2A3 genes coding
GLUT isoform 1 (GLUT1) and isoform 3 (GLUT3), as well as
the regulatory HIF-1α gene and the levels of their correspond-
ing proteins, to investigate their influence on tumor aggres-
siveness and patient prognosis in squamous cell laryngeal
cancer.
Materials and methods
Patients and samples
The study material constituted 106 fresh biopsy tissue samples
obtained from squamous cell laryngeal carcinoma (SCC)
cases, and the control constituted 73 tissue samples from a
morphologically estimated noncancerous laryngeal mucosa
(NCM) from individuals who were qualified for total laryn-
gectomy. According to ethical rules, the adjacent normal
epithelium of the larynx in patients qualified for partial laryn-
gectomy was not sampled. The patients (100 men and 6
women, mean age 62.4±9.1 years) were recruited between
January 2003 and December 2011 and were under treatment at
the Department of Otolaryngology and Laryngological
Oncology, Medical University of Łódź, Poland. All individ-
uals had a confirmed diagnosis of laryngeal carcinoma based
on histopathological evaluation and had undergone partial or
total laryngectomy, depending on the extent of neoplastic
lesions. All fresh samples were stored at −80 °C before the
analyses. The tissue specimens collected in the operation
room were prepared and evaluated by an experienced pathol-
ogist. Normal laryngeal tissues were collected from the sites
as far as possible from the margins of the tumor by individu-
ally harvesting samples from presumptive noncancerous re-
gions. Hematoxylin and eosin (H&E)-stained sections provid-
ed histological confirmation of noncancerous and cancerous
tissues. The criteria for patient participation in this study were
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as follows: (1) a pathologically confirmed diagnosis of squa-
mous cell planoepitheliale carcinoma; (2) primary surgical
resection without receiving prior immunotheraphy,
radiotheraphy, or chemotherapy; (3) absence of distant metas-
tases and second primary neoplasms; (4) a negative history of
previously diagnosed with other types of primary cancers; and
(5) a negative history of recurrences of laryngeal cancer.
Informed consent was obtained from each subject. The inves-
tigations were performed with the approval of the Bioethical
Commission of the Medical University of Łódź and the
National Science Council, Poland (approval No RNN/60/13/
KE). In all cases, surveys were performed to complete the
cancer registry database. The database catalog was queried
every 2 months and identified all histopathologically con-
firmed incident primary squamous cell laryngeal cancer cases
reported within 4 months of diagnosis preceding the recruit-
ment. The sociodemographic features of the study subjects are
shown in Table 1.
Histological classification and morphological features
Archival formalin-fixed paraffin-embedded tissue samples
were used for the histological classification of tumors. All
specimens were assessed according to the criteria conducted
in accordance with the AJCC TNM classification of 2010 for
laryngeal cancers [34]. Morphological estimation was per-
formed on H&E-stained sections in the most invasive, periph-
eral zones of the tumor, according to tumor front grading
(TFG), which is one of the most reliable pathological methods
for the analysis of neoplastic progress and determination of
the dynamics of tumor growth, as well as a reasonably precise
prognostic factor in laryngeal carcinoma [35]. The histologi-
cal evaluation considers the mode and depth of invasion as
well as total TFG score. The factors were assessed in at least
five different regions of the peripheral part of the tumor
(magnification ×200, number of mitoses magnification
×400). Each factor was graded according to a scale ranging
from 1 to 4. The numeric morphological TFG score was
computed as the sum of tumor-related features (cytoplas-
mic differentiation, nuclear polymorphism, number of
mitoses) and adjacent stroma-related characteristics of
the peripheral edge of tumor infiltration (mode of inva-
sion, depth of invasion, and plasmalymphocytic infiltra-
tion), with a maximum score of 24 points. According to
the TFG total score, tumors were divided into four
groups: 6–9, 10–13, 14–17, 18–21, and >22 TFG
points. The clinicopathological characteristics of the la-
ryngeal cancers are shown in Table 2.
RNA isolation and cDNA synthesis
The tissue specimens collected in the operation room were
prepared and evaluated by an experienced pathologist.
Samples were stored at −80 °C until RNA preparation. Total
RNA was isolated using Trizol® Reagent (Sigma-Aldrich,
USA) according to manufacturer’s protocol and quantified
spectrophotometrically. RNAwas eluted in 20 μl RNase-free
water, quantified by spectrophotometry at 260 nm and stored
at −20 °C. RNAwith a 260/280 nm ratio in the range 1.8–2.0
was considered high quality. First-strand complementary
DNAs (cDNAs) were obtained by reverse transcription of
1 μg of total RNA using RevertAid™ first-strand cDNA
synthesis kit (Fermentas International, Lithuania) following
the manufacturer’s protocol.
Table 1 Sociodemographic characteristics of patients with laryngeal
carcinoma
Characteristic Number of
patients (%)
Sample size 106
Median age (range) 62.4 years (45–83)
Median overall
survival (range)
59.3 months (28–79)
Gender Male 100 (94.3)
Female 6 (5.7)
Smoking statusa Current 78 (73.6)
Former 23 (21.7)
Never 5 (4.7)
Alcohol intakeb Never/rare 3 (2.8)
Light 16 (15.1)
Moderate 55 (51.9)
Heavy 27 (25.5)
Ex-drinkers 5 (4.7)
Surgical treatment Total laryngectomy 73 (68.9)
Partial laryngectomy 33 (31.1)
Neck dissection (−) 60 (56.6)
Neck dissection (+) 46 (43.4)
Selective neck dissection 42 (39.6)
Radical neck dissection 4 (13.8)
Survival ≥5 years 69 (86.8)
<5 years 37 (13.2)
Local recurrences No 93 (87.7)
Yes 13 (12.3)
Nodal recurrences No 94 (88.7)
Yes 12 (11.3)
a Smoking was grouped into “current,” “former,” and “never” based on
self-reported usage. Participants who reported smoking at least 100
cigarettes in their lifetime and who, at the time of survey, smoked either
every day or some days were defined as current smoker. Participants who
reported smoking at least 100 cigarettes in their lifetime and who had not
been smoking for at least 3 months were defined as former smoker.
Participants who reported never having smoked 100 cigarettes were
defined as never smoker
b Never/rare, <1 unit/week; light, 1–8.9 units/week; moderate, 9–
17.9 units/week; heavy, ≥18 units/week; where 1 unit=22 g ethanol
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Quantitative real-time RT-PCR
Real-time gene expression analysis of target genes (SLC2A1,
SLC2A3, and HIF-1α) was performed using TaqMan® Gene
Expression Assays (Applied Biosystems, USA) according to
manufac ture r ’s ins t ruc t ions . The hypoxan th ine
phosphoribosyltransferase 1 (HPRT1) gene was used as inter-
nal control. The assay numbers for these genes were as fol-
lows: Hs00892681_m1, Hs00359840_m1, Hs00936368_m1,
and Hs02800695_m1. Each PCR reaction was performed in a
10-μl volume that included 5 μl of 2× TaqManUniversal PCR
MasterMix (Applied Biosystems, USA), 4.5 μl of water di-
luted cDNA template (50 ng), and 0.5 μl of TaqMan® Gene
Expression Assay consisted of a pair of unlabeled PCR
primers and TaqMan probe with a FAM™. The RT-qPCR
reaction was carried out using the Mastercycler ep realplex
(Eppendorf) under the following conditions: denaturation for
10 min at 95 °C followed by 50 cycles of 15 s at 95 °C, 1 min
annealing and extension at 60 °C. Relative RNA
quantification was performed using the ΔCt method. ΔCt
(Ctgene−CtHPRT1) values were recalculated into relative copy
number values (number of SLC2A1, SLC2A3, and HIF-1α
mRNA copies per 1000 copies of HPRT1 mRNA).
SLC2A1 and SLC2A3 gene copy number quantification
To determine the SLC2A1 and SLC2A3 gene amplification,
copy number quantification was carried out using quantitative
real-time PCR Mastercycler ep realplex (Eppendorf) with the
glucokinase (GCK) gene used as the reference gene. The real-
time PCR primers are as follows: SLC2A1 (f) 5′-TGTGCAAC
CCATGAGCTAA-3′, SLC2A1 (r) 5′-CCTGGTCTCATCTG
GATTCT-3′; SLC2A3 (f) 5′-TTCGTCTCTAGCCTGCACTG
-3′, SLC2A3 (r) 5′-ACACAACTTCTCCGGGTGAC-3′;
GCK(f) 5 ′-CGGATGCAGAAGGAGATGGA-3′, and
GCK(r) 5′-CATCTTCACACTGGCCTCTTCA-3′. Real-time
PCR was performed in 50-μl reaction volumes that contained
2× Power SYBR Green PCR Master Mix (Applied
Biosystems, USA) and 0.9 mM forward and reverse primers.
PCR conditions were as follows: 5 s at 95 °C followed by
40 cycles consisting of 15 s at 95 °C and 30 s at 60 °C. ΔCt
was calculated by a Ct value of GCK taking away that of
SLC2A1 and SLC2A3 and three or more ΔCt was defined as
amplified.
Western blotting analysis
The protein content of the tissue homogenate fraction was
estimated by means of the modified Lowry procedure [36]
using bovine serum albumin (BSA) as standard. The samples
(50 μg protein/lane) of homogenates were resolved by 8 %
SDS-PAGE and electroblotted onto Immobilon-P transfer
membranes (Millipore, Bedford, MA, USA). The blots were
incubated 1 h with rabbit polyclonal anti-GLUT1 (Abcam,
UK), mouse monoclonal anti-GLUT3 (Santa Cruz
Biotechnology, Inc., USA) or rabbit polyclonal anti-HIF-1α
antibodies (Santa Cruz Biotechnology, Inc., USA) in a
1:1000, 1:400, and 1:1000 dilution, respectively. After being
washed three times with Tris-buffered saline with Tween-20
(TBST), the membranes were incubated 1 h with goat anti-
rabbit or anti-mouse antibodies conjugated with horseradish
peroxidase (1:5000 dilution). The membranes were again
washed three times with TBSTand incubated with peroxidase
substrate solution (3,3′-diaminobenzidine (DAB)). Gel-Pro®
Analyzer software (Media Cybernetics Inc., USA) was used
for densitometry analysis of protein bands. The integrated
optical density (IOD) of the bands, in a digitized picture,
was measured. For the immunoblot analysis, an IOD less than
5 was taken as negative.
All RT-PCR andWestern blot reactions were repeated three
times for each sample.
Table 2 Clinicopathological characteristics of laryngeal cancers
Characteristics Cases (%)
Tumor size
(pT status)
pT1 10 (9.4)
pT2 29 (27.4)
pT3 33 (31.1)
pT4 34 (32.1)
Lymph node
metastases
(pN status)
pN0 84 (79.2)
pN1-3 22 (20.8)
Degree of
differentiation
(grade)
G1 14 (13.2)
G2 82 (77.4)
G3 10 (9.4)
TFG total scorea 6–9 points 5 (4.7)
10–13 points 39 (36.8)
14–17 points 39 (36.8)
18–21 points 23 (21.7)
>22 points 0
Mode of invasion 1—Well-defined borderline 14 (13.2)
2—Less marked borderline 34 (32.1)
3—No distinct borderline 37 (34.9)
4—Diffuse growth 21 (19.8)
Depth of invasion 1—Carcinoma in situ 5 (4.7)
2—Microinvasion 35 (33.0)
3—Nodular into submucosa 27 (25.5)
4—Deep invasion (cartilage infiltratio) 39 (36.8)
a The numeric morphological TFG score was computed as the sum of six
tumor-related features (cytoplasmic differentiation, nuclear polymor-
phism, number of mitoses) and adjacent stroma-related characteristics
of the peripheral edge of tumor infiltration (mode of invasion, depth of
invasion, and plasmalymphocytic infiltration). The factors of TFG were
assessed in at least five different regions of the peripheral part of the
tumor (magnification ×200, number of mitoses magnification ×400).
Each factor was graded according to a scale ranging from 1 to 4
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Statistical analysis
The statistical analyses were performed using STATISTICA
version 9.0 (StatSoft, Poland). Since levels of expression in
endometrial and breast cancer specimens did not follow a
normal distr ibution (Kolmogorov-Smirnov test) ,
nonparametrical statistical tests were applied (Mann-
Whitney U test, Spearman’s rank analysis). Kruskal-Wallis
test with post hoc multiple comparisons was used according to
clinical data. Kaplan-Meier survival analysis was performed
to determine the association of SLC2A1, SLC2A3, and HIF-
1α mRNA expression with overall survival. The cutoff value
was established to be the median of SLC2A1, SLC2A3, and
HIF-1α mRNA level. The survival curves were compared
between two groups: high (≥ median value) and low (<
median value) expression using log-rank tests. Distribution
of quantitative variables was described using means and stan-
dard deviations. A p value <0.05 was considered as statisti-
cally significant.
Results
SLC2A1, SLC2A3, and HIF-1α gene expression in neoplastic
and noncancerous tissues
The mRNA expression of genes SLC2A1, SLC2A3, and HIF-
1α in either SCC or NCM was estimated by real-time quan-
titative PCR analysis withHPRT1 gene applied as a reference.
A positive expression of SLC2A1 and SLC2A3 transcripts was
confirmed in 83.9 % (89/106) and 82.1 % (87/106) samples of
laryngeal cancer, respectively. In the case of normal tissue,
positive expression of GLUT1 and GLUT3 mRNAwas dem-
onstrated in 49.3 % (36/73) and 43.8 % (32/73) of samples,
respectively. Positive expression ofHIF-1α gene was noted in
71.7 % (76/106) of SCC and in 9.6 % (7/73) of NCM,
respectively. Thus, positive expression of both GLUT tran-
scripts and HIF-1α was more frequent in SCC than in NCM.
A significant difference was noted in the levels of GLUT1
and GLUT3 mRNA in laryngeal cancer tissue compared to
adjacent normal laryngeal tissue (p<0.001 and p<0.001, for
the SLC2A1 and SLC2A3 genes, respectively). The relative
expression of SLC2A3 transcripts was much lower than
SLC2A1 in both SCC and NCM. Similarly, mean mRNA
expression of the HIF-1α gene in neoplastic tissue was also
higher than that in normal laryngeal tissue, but the difference
was not significant (p>0.05). Mean GLUT1, GLUT3, and
HIF-1α gene expression in SCC and NCM, as well as the
results of statistical analysis, are summarized in Table 3. No
significant correlation was found between GLUT1 and
GLUT3 mRNA expression levels (Spearman’s rank analysis,
p>0.05). However, a significant correlation was found
between expression of the HIF-1α gene with SLC2A1 tran-
scripts (Spearman’s rank analysis, r=0.21, p=0.04), but not
SLC2A3 transcripts (Spearman’s rank analysis, p>0.05), as
determined by real-time PCR. The expression of HIF-1α
mRNA in relation to SLC2A1 and SLC2A3 genes in laryngeal
cancer is shown in Fig. 1.
Gene copy number analysis revealed that SLC2A1 gene
amplification was observed in 2 % (2/106) of laryngeal cancer
cases, but in none of the normal tissue samples. In the case of
SLC2A3 gene, amplification was confirmed neither in cancer-
ous nor normal tissues.
Association between SLC2A1, SLC2A3, and HIF-1α
transcripts and tumor behavior
The expression of SLC2A1, SLC2A3, and HIF-1α transcripts
with regard to relevant clinicopathological parameters in la-
ryngeal cancers is shown in Table 4. The mRNA level of
genes coding GLUT1 and GLUT3 significantly increased
together with the degree of histological differentiation (p=
0.0005 and p=0.003, respectively). Significant differences
were noted between grade 1 and grade 3 tumors as well as
between grade 1 and grade 2 positive cancers with regard to
SLC2A1 expression (p<0.001 and p<0.05, respectively), as
well as between grade 3 and both grade 1 and 2 positive
cancers with regard to SLC2A3 expression (p<0.01 and
p<0.05, respectively). No differences in SLC2A1 and
SLC2A3 gene level were noted with respect to other pTNM
parameters (p>0.05). However, the results showed that more
advanced tumors (pT3-4, pN1-3) were more likely to be more
frequently positive and to have a higher mean levels for both
SLC2A1 and SLC2A3 transcripts than less advanced cancers
(pT1-2, N0).
SLC2A1 mRNA expression was significantly higher in
laryngeal TFG cancers with a total score ≥14 points than less
aggressive ones (p=0.021). Moreover, SCC characterized by
deep invasion with submucosa or cartilage infiltration (3–4
points) and by diffuse growth or invasion with no distinct
borderlines (3–4 points) demonstrated significantly higher
levels SLC2A1 mRNA in comparison with less invasive tu-
mors (p=0.028 and p=0.021, respectively). Mean SLC2A3
gene expression was significantly higher in more disseminat-
ed invasion type cancers (p=0.0001). Furthermore, SLC2A1
transcript level was also significantly related to disease-free
survival when compared <5- and ≥5-year categories.
Increased GLUT1 expression was found to be associated with
a survival time of less than 5 years (p=0.012). SLC2A1
expression was found to have no connection with the inci-
dence of local and nodal recurrences (p>0.05). No significant
differences were found between SLC2A3 mRNA level and
either recurrence or 5-year disease-free survival (p>0.05). The
association between clinicopathological parameters and the
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expression of SLC2A1 and SLC2A3 transcripts, as well as with
the results of the statistical analysis, are shown in Fig. 2.
The HIF-1α mRNA level significantly increased with the
size of the primary tumor (pT3-4) (p<0.001), the presence of
nodal metastases (pN1-3) (p<0.001), and tumor grade
(p=0.004). Moreover, laryngeal cancers with TFG total
score ≥14 points, deep invasion (3–4 points), and dis-
seminated growth (3–4 points) were noted to have sig-
nificantly higher HIF-1α gene level compared to less
invasive tumors (p<0.001, p<0.001, and p<0.001, re-
spectively). In addition, increased expression of the
gene coding HIF-1α was found to promote a survival
time of less than 5 years (p<0.001) and the presence of
local and nodal recurrences (p<0.001 and p<0.001,
respectively). The relationship between various clinico-
pathological parameters and HIF-1α gene expression, as
well as with the results of the statistical analysis, is
shown in Fig. 3.
Moreover, overall survival was analyzed through the
Kaplan-Meier plots, as shown in Fig. 4. Mean overall
survival time was 67.8 and 60.6 months in low and
high SLC2A1 expression groups, respectively. Similarly,
mean overall survival time was 66.4 months in low
SLC2A3 mRNA expression and 64.2 months in high
SLC2A3 expression. No significant differences were
found in GLUT1 and GLUT3 expression in relation to
prognosis (p>0.05). However, the results revealed a
trend of worse overall survival rate in cases with a high
expression of the GLUT1 and GLUT3. Mean overall
survival time was 76.8 months in low HIF-1α mRNA
expression and 52.5 months in high HIF-1α expression.
A significant shorter overall survival for a higher HIF-
1α gene expression was estimated (p<0.001).
GLUT1, GLUT3, and HIF-1α protein expression
in neoplastic and noncancerous tissues
In the next stage, expression of GLUT1, GLUT3, and HIF-1α
was examined on the protein level using Western blotting
analysis, in homogenate samples of both SCC and NCM
specimens. The 32 tissue samples selected for quantitative
Table 3 Mean SLC2A1,
SLC2A3, HIF-1α gene and
related protein expression in
cancerous and normal tissues
Results are given as mean±
standard deviation
SCC squamous cell laryngeal
cancer, NCM noncancerous
laryngeal mucosa
mRNA gene expression
(copies of gene mRNA
per 1000 copies of
HPRT1 mRNA)
p value Protein expression
(integrated optical
density)
p value
Gene/Protein SLC2A1 GLUT1
SCC 353.72±226.42 97.83±35.51
NCM 156.42±92.15 <0.001 48.17±32.67 0.032
SLC2A3 GLUT3
SCC 176.09±173.38 118.63±64.22
NCM 21.56±11.21 <0.001 0 −
HIF-1α HIF-1α
SCC 564.68±481.99 179.1±245.34
NCM 44.29±153.69 <0.0001 76.21±97.44 0.11
Fig. 1 Spearman’s rank analysis results for HIF-1α mRNA expression
level in relation to SLC2A1 (a) and SLC2A3 (b) genes in laryngeal cancer
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densitometric analysis were representative for whole group
studied and characterized by similar distribution, based on the
pTNM classification. Of the carcinoma tissue samples, 34.4%
(11/32) and 59.4 % (19/32) showed GLUT1- and GLUT3-
positive expression, respectively. In the case of matched nor-
mal laryngeal tissue, GLUT1 protein expression was observed
in 31.3 % of samples and GLUT3 in none. The results of the
quantitative densitometric analysis of the intensity of GLUT1
and GLUT3 bands in homogenates of normal and cancerous
tissues are shown in Fig. 5. Positive HIF-1α protein expres-
sion was noted in 62.5 % (20/32) of SCC and in 15.6 % of
NCM, respectively. Mean protein expression of GLUT1 and
HIF-1α in SCC were higher compared to NCM, but only
GLUT1 protein level was found to be significantly different
(p=0.032). Mean GLUT1, GLUT3, and HIF-1α protein ex-
pression in SCC and NCM and statistical analysis results are
shown in Table 3.
Association between GLUT1, GLUT3, and HIF-1α proteins
and the tumor behavior
GLUT and HIF-1α expression was also compared with the
pTNM classification of laryngeal cancer cases, since the tu-
mor stage is currently the only accepted prognostic marker.
Despite the relatively small size of positive results for the
presence of proteins studied and the small proportion of
subcategories of pTNM classification, the results show a clear
relationship between quantitative densitometric results and
stage parameters.
The results reveal a trend of more advanced tumors to have
more common positive expression of GLUT1, GLUT3, and
HIF-1α proteins, according to Western blot analysis. The posi-
tive expression of GLUT1 andGLUT3 proteins in SCC samples
according to pTNM categories was as follows: 33.3 % (5/15) in
pT1-T2 and 35.3 % (6/17) in pT3-T4 tumors, 18.8 % (4/22) in
pN0 and 70% (7/10) in pN1-3 for GLUT1, and 46.7% (7/15) in
pT1-T2 and 70.6 % (12/17) in pT3-T4 tumors, 50 % (11/22) in
pN0 and 80 % (8/10) in pN1-3 for GLUT3. It should be also
emphasized that higher graded tumors were found to demon-
strate higher expression of the GLUT1 protein, but not GLUT3.
The results concerning GLUT1 and GLUT3 expression in ho-
mogenate samples of laryngeal cancer tissues in relation to
tumor grade are shown in Fig. 5.
Similar trends were demonstrated for the HIF-1α protein.
The levels of positive HIF-1α expression according to pTNM
categories and histological grade was as follows: 26.7 %
(4/15) in pT1-T2 and 94.1 % (16/17) in pT3-T4 tumors,
54.5 % (12/22) in pN0 and 80 % (8/10) in pN1-3 and 10 %
Table 4 Expression of SLC2A1,
SLC2A3, and HIF-1α gene in
laryngeal cancers
Characteristics SLC2A1 SLC2A3 HIF-1α
Positive/total
(%)
Positive/total
(%)
Positive/total
(%)
Tumor size (pT status) pT1 8/10 (80.0) 8/10 (80.0) 2/10 (20.0)
pT2 24/29 (82.8) 23/29 (79.3) 13/29 (44.8)
pT3 28/33 (84.8) 28/33 (84.8) 27/33 (81.8)
pT4 29/34 (85.3) 28/34 (82.4) 34/34 (100.0)
Lymph nodemetastases (pN status) pN0 68/84 (80.9) 73/84 (86.9) 54/84 (64.3)
pN1-3 21/22 (95.5) 14/22 (63.6) 22/22 (100.0)
Degree of differentiation (grade) G1 10/14 (71.4) 11/14 (78.6) 6/14 (42.8)
G2 69/82 (84.1) 67/82 (81.7) 62/82 (75.6)
G3 10/10 (100.0) 9/10 (90.0) 8/10 (80.0)
TFG total score <14 points 35/44 (79.5) 29/44 (65.9) 17/44 (38.6)
≥14 points 54/62 (87.1) 58/62 (93.5) 59/62 (95.2)
Mode of invasion 1–2 points 32/48 (66.7) 35/48 (72.9) 18/48 (37.5)
3–4 points 57/58 (98.2) 52/58 (89.6) 58/58 (100.0)
Depth of invasion 1–2 points 33/40 (82.5) 26/40 (65.0) 14/40 (35.0)
3–4 points 56/66 (84.8) 61/66 (92.4) 62/66 (93.9)
Survival ≥5 years 58/69 (84.1) 64/69 (92.8) 40/69 (58.0)
<5 years 31/37 (83.8) 30/37 (81.1) 36/37 (97.3)
Local recurrences No 79/93 (84.9) 76/93 (81.7) 63/93 (67.7)
Yes 12/13 (92.3) 11/13 (84.6) 13/13 (100.0)
Nodal recurrences No 76/94 (80.9) 76/94 (80.9) 64/94 (68.1)
Yes 11/12 (91.7) 11/12 (91.7) 12/12 (100.0)
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(1/10) for well-differentiated tumors, 75 % (9/12) for
moderately-differentiated cancers, and 100 % (10/10) for
poorly-differentiated tumors.
Discussion
In the last decade, a growing body of evidence indicates that
increased level of glycolytic activity observed under aerobic
conditions (the Warburg effect) needed to meet the energy
requirements of tumor cells and the endogenous markers of
metabolism/hypoxia may contribute to the development, pro-
liferation, angiogenesis, and progression of various types of
head and neck cancers [1–5]. Studies have linked GLUT
function to cancer cell dynamics and tumor pathology, yet
findings remain limited and often divergent, especially regard-
ing the impact of their specific isoforms on tumor invasion
and prediction of patient outcome [15–26]. The activity of the
glycolytic pathway may also be responsible for
a b
c d
fe
Fig. 2 Expression of SLC2A1
and SLC2A3 mean mRNA
measured by real-time PCR in
laryngeal cancers; a comparison
between subgroups with
histological differentiation
(grade) (a), total score of tumor
front grading (b), depth of
invasion (c), mode of invasion
(d), 5-year survival (e), and local
recurrences (f). Graphs represent
mean±standard deviation.
*p<0.005, **p<0.001,
***p<0.0001
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radioresistance and chemoresistance and thus may affect pa-
tient prognosis [27, 28, 37].
Our study documents for the first time the relationship
between the expression of GLUT1 and GLUT3 isoforms in
the fresh human biopsy material and the dynamics of tumor
growth in laryngeal cancer, according to a precise, multifac-
torial histological analysis of tumor front aggressiveness.
Importantly, the material studied constitutes a homogeneous
and numerous groups of head and neck cancers sharing the
same origin. This composition of the study groups adds to the
value of this research, when the difficulties in obtaining fresh
human biopsy tissues such as cancerous and matched normal
tissues are taken into consideration. It should be also noted
that, due to these difficulties, the overwhelming majority of
previous studies have used cell cultures and paraffin-
embedded archival material, often also limited in number,
which doubtlessly have an impact on the final results. In this
study, the protein expression in less material due to this
limitation complements research on the genes studied.
A literature search indicates that no studies on the amplifi-
cation of the SLC2A1 and SLC2A3 genes in fresh tissues from
the head and neck region have yet been performed. Since
copies of the studied genes were found in only 2 % cases of
laryngeal carcinoma, it can be concluded that SLC2A1 and
SLC2A3 amplification does not affect the expression of
GLUT1 and GLUT3 in this type of neoplasm.
The resulting data concerning expression of GLUT iso-
forms in laryngeal cancer resembles the findings of other
researchers [28, 38–40]. However, it should be noted that a
literature survey revealed only a few studies on these relation-
ships in head and neck cancer. For instance, Zhou et al. [22]
reported that the expression of the GLUT1 and GLUT3 genes
were significantly higher in cancerous tissue than in adjacent
normal tissue in 38 head and neck cancer samples. A similar
result was reported by Burstein et al. [38] for 27 cases of
squamous intraepithelial neoplasia and 26 invasive carcino-
mas of the head and neck region. In this study, upregulation of
GLUT1 at the protein level was established in tumor speci-
mens compared with normal epithelium, characterized by
negativity or weak/equivocal staining. Previous studies have
also reported a lower prevalence or absence of HIF-1α in
noncancerous tissue of various head and neck tumors [39,
40]. For example, Zhang et al. [39] observed an overexpres-
sion of both GLUT1 and HIF-1α proteins in 85 neoplastic
tissues of oral squamous cell cancer and conclude these
metabolism/hypoxia-related proteins can be predictive
markers for malignant conversion of oral premalignant epi-
thelial dysplasia. Similarly, Xie et al. [40] confirmed enhanced
Fig. 3 Expression of HIF-1α
mean mRNA measured by real-
time PCR in laryngeal cancers; a
comparison between subgroups
with histological differentiation
(grade) (a), total score of tumor
front grading (b), depth of
invasion (c), mode of invasion
(d), 5-year survival (e), and local
recurrences (f). Graphs represent
mean±standard deviation.
*p<0.05, **p<0.01, ***p<0.001
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immunostaining for HIF-1α in 56 laryngeal cancer tissues and
its negative expression in normal mucosa specimens.
In addition, a literature review reveals a wide range of
findings concerning expression rate and distribution of
GLUTs in various head and neck cancers. The data
concerning the expression of GLUT1 and GLUT3 transcripts
or, most often, protein immunoexpression identified in laryn-
geal cancer cases were found to be very similar to ours: the
mean frequency of GLUT1 was in the range 50.3–98 % while
GLUT3 positive expression was less so [8, 18, 21, 22, 24–26].
The reasons for lower GLUT3 mRNA/protein expression in
various cancer specimens may be, on the one hand, the
Fig. 4 Kaplan-Meier plots of overall survival for categorized by SLC2A1
(a), SLC2A3 (b), and HIF-1α (c) mRNA expression in homogenate
samples of laryngeal cancer tissues. The cutoff value was established to
be the median of the SLC2A1, SLC2A3, and HIF-1α mRNA levels. The
survival curves were compared between two groups: high (≥ median
value) and low (< median value) expression
a
b
Fig. 5 Representative immunoblot and quantitative analysis results of
GLUT1 (a) and GLUT3 (b) protein expression in homogenate samples
(50 μg protein loaded per lane) of normal (lane 1) and laryngeal cancer
tissues (lanes 2–4) in relation to tumor grade. Lower panels show the
results of quantitative densitometric analysis: lane 1, normal laryngeal
mucosa, lanes 2–4, laryngeal cancer samples classified according to the
three-grade morphological system as G1 (well-differentiated tumor), G2
(moderately-differentiated tumor), and G3 (poorly-differentiated tumor),
respectively
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activity of other GLUT isoforms, i.e., GLUT1, which are
responsible for the glucose uptake and glycolytic metabolism,
and on the other hand, due to heterogeneity of GLUT expres-
sion within tumor tissues. In addition, laryngeal cancers often
have numerous foci of necrosis, where glucose metabolism is
less pronounced and may result in lower expression of the less
active GLUT3 isoform [41]. Therefore, our analysis has been
restricted to areas without tumor necrosis. It is not without
significance that HIF-1α activity, which determines GLUT
expression, is also not ubiquitous and heterogenous in cancer-
ous tissue and increases with the distance of the sampling site
from the blood vessels [42].
Studies have confirmed the role of GLUT isoforms, mainly
GLUT1, in head and neck neoplastic lesions and both cancer
development, tumor progression and patient prognosis, but
many demonstrate equivocal and divergent results [15–26].
Importantly, most which address invasive behavior concern
only standard clinical parameters (TNM classification, grade)
and survival time.
Most studies confirm the increased expression of GLUTs in
more advanced head and neck cancers, where a positive
association was found for clinical variables including tumor
grade and stage [8, 18, 22, 26, 43]. For instance, Wu et al. [8]
reported enhanced GLUT1 isoform expression in a studied
population of 49 laryngeal cancer cases and identify a positive
association between GLUT1 immunostaining and primary
tumor site, lymph node invasion, and recurrences. Similarly,
Ayala et al. [18] estimated a positive association of GLUT3
immunoexpression with advanced clinical tumor stage and
vascular embolization in laryngeal cancer. Kondo et al. [26]
also revealed a correlation between increased GLUT1 IHC
expression in primary oral cancer tissues with advanced nodal
metastatic stage but, as identified by the present study, not
with the survival rate. Zhou et al. [22] indicated that higher
GLUT1 and GLUT3 mRNA levels in head and neck carcino-
mas may also have an effect on advanced clinical stage and
positive lymph node status. The distributions of hypoxia/
metabolic markers in oral tongue cancer described by Roh
et al. [43] confirm those given in the present study. The
researchers suggest that GLUT1 expression contributes to
tumor thickness and nodal classification. Also, Demasi et al.
[19] revealed that overexpression of GLUT1 corresponds to
lower histological tumor differentiation in patients with sali-
vary gland carcinoma, which confirms our results. Ciampi
et al. [21] performed an analysis of GLUT expression in
human thyroid primary carcinoma tissues and cell lines to
determine the impact of GLUT1 on tumor histological differ-
entiation. The authors note that the occurrence of positive
GLUT1 expression is frequently characteristic of anaplastic
tumors compared with well-differentiated cancers. By con-
trast, overexpression of GLUT3 mRNA in this cell cancer
model corresponds to lower tumor grade. It was also deter-
mined that the protein level of this isoform in fresh tissue
samples is not detectable. However, Ohba et al. [20] suggest
that upregulation of GLUT1 protein level may play a crucial
role in determining the depth of invasion but bears no relation
with primary tumor size and nodal metastases in oral
carcinoma.
Nevertheless, contrary results for GLUT1 and GLUT3
immunoexpression related to such clinical parameters as pri-
mary tumor size, extrathyroidal extension, and lymph node
metastases has also been reported by Kaida et al. [23]. This
data is confirmed by Kwon et al. [37] in a study of 42 early-
stage laryngeal cancers, which notes that GLUT1 was not
found to exert any influence on residual tumor or survival
after radiotherapy. Subsequently, no association between
GLUT1 level in malignant oesophageal cancer samples and
pN stage was shown by Kobayashi et al. [16]. However,
similar to our results, the authors reported enhanced GLUT1
immunostaining in individuals with more locally advanced
carcinomas in this region of the head and neck.
Unfortunately, the relationship between GLUT level and
prognosis was also found to be divergent in the head and neck
cancer populations. The obtained data confirms that GLUT
isoform expression was unrelated to mortality. The prognosis
results described byMüssig et al. [25] were almost the same as
those given in the present study. Higher GLUT1
immunoexpression has been found not to be associated with
clinical outcome in the thyroid cancer population. Similarly,
Schrijvers et al. [44] reported different findings regarding
GLUT1 immunostaining in 91 early-stage glottic carcinomas
treated with radiotherapy only. In this case, GLUT1 overex-
pression was found to be not significantly related to the
clinical outcome parameters.
However, other researchers report different findings and
conclude that GLUT activity may be implicated in patient
survival time. For instance, Ohba et al. [20] suggested that
upregulation of GLUT1 protein level may affect prognosis in
patients with oral carcinoma. Similarly, Zhou et al. [22] ob-
served that individuals having GLUT1 positive gene expres-
sion demonstrated considerably shorter overall survival, but
no association was found between GLUT3 transcript and
prognosis in the studies head and neck cancer populations.
Less controversy and fewer conflicting results concern the
clinical and prognostic value of HIF-1α and its relationship
with glucose metabolism molecules in head and neck cancers
[8, 45]. Our study shows a strong positive correlation between
the activity of HIF-1α and GLUT1, but not GLUT3, and
indicates its association with a higher advancement of neo-
plastic lesions and poor patient outcome. The literature also
offers a considerable body of evidence for the role of HIF-1α
in carcinogenesis and the metabolic regulation of GLUTs, thus
confirming our observations. For example, Wu et al. [8]
demonstrated a significant correlation between HIF-1α and
GLUT1 expression and report that increased hypoxia/
metabolism markers are independent predictors of
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recurrences, lymph nodemetastases, and shortened survival in
laryngeal cancer. Similarly, Yamada et al. [45] confirmed the
significant coexpression of HIF-1α and GLUT1 in early-stage
tumors in squamous cell oral cancers.
A few studies concerning HIF-1α expression in relation to
tumor behavior and prognosis in head and neck carcinomas
also confirm our findings [29–31]. Li et al. [31] reported that
HIF-1α could be regarded as a potential predictor of a higher
clinical stage and nodal metastases of laryngeal carcinoma.
Also, Koperek et al. [30] suggested that HIF-1α contributes to
a higher pN status and peritumoral/extrathyroidal infiltration,
as well as angioinvasion in thyroid carcinoma. Ping et al. [29]
noted that HIF-1α overexpression was found to be signifi-
cantly related to stage, nodal metastases, depth of invasion,
local recurrences, and clinical outcome in esophageal cancer.
Unfortunately, a few studies present inconsistent data re-
garding the status of HIF-1α as a biomarker of tumor inva-
siveness and prognosis [32, 33]. For example, Douglas et al.
[32] noted a lack of prognostic effect of HIF-1α overexpres-
sion in patients with early squamous cell carcinoma of the
glottis treated with radiotherapy. Also, Cabanillas et al. [33]
observed that HIF-1α expression correlated with the tumor
local extension but was not associated with tumor stage or
lymph node metastases in supraglottic laryngeal cancer.
Finally, it should be also stressed that there are limitations
to our study. While GLUT1 and GLUT3 expression could be
considered as useful potential biomarkers for tumor behavior
in laryngeal cancer, discrepancies exist for other tumors of this
region due to variation of tumor types, histological differenti-
ation status, and proliferative index, which cause differences
in their biology. Admittedly, the results indicate the issue role
of GLUTs and interactions with HIF-1α as their key regulator
in cancers, but it is not clearly understood and there is a need
for future research to clarify the relevance of GLUT proteins
in carcinogenicity and the behavior of various tumors. Also,
because of the limited amount of biological material in our
study, GLUTs and HIF-1α were compiled with regard to
protein expression only, with pTNM classification, the cur-
rently accepted prognostic parameters, being used in a smaller
number of laryngeal cancer cases.
Conclusions
In conclusion, our findings suggest that both the SLC2A1 and
SLC2A3 genes, as well as the related GLUT1 and GLUT3
proteins, can affect the behavior of laryngeal cancer.
Moreover, our findings indicate the importance of the expres-
sion of GLUTs as a significant factor in determining tumor
aggressiveness, which should be taken into consideration in
choosing alternative and optimal treatment modalities, i.e.,
extension of primary surgical procedure, and can contribute
to prognosis in patients with cancer of the larynx. However,
additional data on SLC2A1 and SLC2A3 genes and their
products in head and neck carcinomas is needed to elucidate
the biological function of GLUTs in carcinogenesis, tumor
progression, and patient outcome.
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